Lucid Diagnostics Inc. (NASDAQ: LUCD)

Lucid Diagnostics Inc., known by its ticker symbol LUCD, is a commercial-stage medical diagnostics technology company operating within the healthcare industry. The company is dedicated to addressing the needs of the millions of patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). Lucid Diagnostics' flagship product, the EsoGuard Esophageal DNA Test, is a bisulfite-converted targeted next-generation sequencing (NGS) DNA assay that analyzes surface esophageal cells collected with the EsoCheck Esophageal Cell Collection Device.

Lucid Diagnostics' primary business activities revolve around the development and commercialization of innovative medical technologies aimed at the early detection and prevention of esophageal precancer and cancer. The company operates primarily within the United States, although its impact is global due to the prevalence of GERD and EAC.

The company generates revenue through the sale of its EsoGuard and EsoCheck products. These tests are used to detect esophageal precancer and cancer in patients with GERD. The primary customers of Lucid Diagnostics are primary care and gastroenterology physicians who order the tests for their patients.

EsoGuard, a bisulfite-converted targeted next-generation sequencing (NGS) DNA assay, quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1). The test is performed on surface esophageal cells collected with the EsoCheck Esophageal Cell Collection Device. EsoGuard has demonstrated a high level of accuracy in detecting esophageal precancer and cancer, with an analytical sensitivity of approximately 97%, analytical specificity of 95%, and analytical accuracy of 98%. EsoCheck is a noninvasive swallowable balloon capsule catheter device that collects surface esophageal cells in a less than five-minute office procedure.

Esophageal adenocarcinoma (EAC) poses a significant market opportunity for Lucid Diagnostics. Approximately 20,000 U.S. GERD patients are projected to be diagnosed with EAC in 2023, and approximately 16,000 will die from it. Lucid Diagnostics believes its EsoGuard and EsoCheck products have the potential to expand the funnel of BE-EAC patients who will need long-term EGD surveillance and potentially treatment with endoscopic esophageal ablation.

Lucid Diagnostics has established a commercialization strategy that includes targeting primary care and gastroenterology physicians, and establishing a network of Lucid Test Centers and satellite test centers. The company has also launched a direct contracting strategic initiative to engage directly with large administrative services only (ASO) self-insured employers, unions, and other entities.

Regarding reimbursement and market access, Lucid Diagnostics has secured a gap fill determination for EsoGuard's PLA code 0114U through the CMS CLFS process, allowing the company to engage directly with Medicare contractor Palmetto GBA and its MolDx Program on CMS payment and coverage. The company has received FDA 510(k) clearance for EsoCheck and CE Mark certification for both EsoCheck and EsoGuard.

The U.S. market for esophageal cancer and pre-cancer testing is large and competitive. Lucid Diagnostics faces competition from procedure-based detection technologies such as upper endoscopy and other testing technologies such as multi-cancer early detection products. However, the company's focus on esophageal precancer and cancer, as well as its advanced EsoGuard and EsoCheck technologies, provide Lucid Diagnostics with a competitive advantage.

EsoCure, a novel technology that allows clinicians to treat dysplastic BE before it can progress to EAC, is a promising addition to Lucid Diagnostics' product portfolio. The company has licensed the rights to commercialize EsoCure from PAVmed and plans to market the product as a treatment for dysplastic BE.

Lucid Diagnostics is a majority-owned subsidiary of PAVmed, with PAVmed holding a controlling financial interest in the company. PAVmed provides Lucid Diagnostics with various management, technical, research and development, legal, accounting, and administrative services. This relationship enables Lucid Diagnostics to leverage PAVmed's expertise and resources to strengthen its operations and growth prospects.